Thema Consulting

Publications

List of publications that THEMA staff have contributed to:

2016

Tilden D, Guarnieri C. Cost-Effectiveness of Incobotulinumtoxin-A with Flexible Treatment Intervals Compared to Onabotulinumtoxin-A in the Management of Blepharospasm and Cervical Dystonia. Value Health. 2016 Mar;19(2):145-52.

2015

Tilden D, Makino K, Cottrell S, Needham M. Quantifying The Cost And Quality Of Life Implications Of Adverse Events Associated With Long-Term Oral Corticosteroid Use. Value Health. 2015 Nov;18(7):A688.

Niven RM, Simmonds M, Cangelosi M, Shargill NS, Tilden D, Cottrell S. Indirect comparison of Bronchial Thermoplasty (BT) versus Omalizumab (OM) for severe uncontrolled Asthma. European Respiratory Society International Congress 2015 (Amsterdam, The Netherlands: September 26-30, 2015. Poster # PA1020.

Tilden D, Guarnieri C, Jackson D. Cost-Effectiveness of Incobotulinumtoxin-A With Flexible Treatment Intervals Compared to Onabotulinumtoxin-A In The Management of Blepharospasm And Cervical Dystonia. Value Health. 2015 Nov;18(7):A759.

2014

Makino K, Tilden D, Kamei M, Shibata K. Risk-Sharing Agreements In Australia: Attitude Towards Risk-Sharing Arrangements With The Department Of Health For The Pbs-Listing Of Pharmaceuticals. Value Health. 2014 Nov;17(7):A801.

Maguire B, Makino K, Tilden D, Ballmer A, Hart S. Health Care Resource Requirements and Costs During the Recovery Phase of Fasciectomy for the Treatment of Dupuytren's Contracture: Clinician Survey. Value Health. 2014 Nov;17(7):A773.

McBride M, Krum H, Schlaich M, Whitbourn R, Walton T, Tilden D, Gillespie J. Effectiveness of Catheter-Based Renal Denervation for Treatment Resistant Hypertension – Results of a Systematic Review and Meta-Analysis. Value Health. 2014 Nov;17(7):A757-A758.

Tilden D, McBride M, Whitbourn R, Krum H, Walton T, Gillespie J. Cost effectiveness of Catheter-based Renal Denervation for treatment resistant hypertension - An Australian payer perspective. Value Health. 2014 Nov;17(7):A762.

2013

Makino K, Arora N, Tilden D, Bingham W. Cost-Effectiveness of Capsule Endoscopy (Pillcam®) in the Diagnosis of Small Bowel Crohn’s Disease. Value Health. 2013 Nov;16(7):A498.

Burri H, Sticherling C, Wright D, Makino K, Smala A, Tilden D. Cost-consequence analysis of daily continuous remote monitoring of implantable cardiac defibrillator and resynchronization devices in the UK. Europace. 2013 Nov;15(11):1601-8.

Maquire B, Tilden D. Key drivers of PBAC decisions for the reimbursement of Orphan Drugs on the Life Saving Drugs Program. Value Health. 2013 Nov;16(7):A480-A481.

Sugden P, Cottrell S, Tilden D, Ballmer A. Systematic Review comparing the efficacy and safety of Collagenase Clostridium Histolyticum (Xiaflex®) Injection with Surgical Fasciectomy for the treatment of Dupuytren's Contracture. Value Health. 2013 Nov;16(7):A556.

Tilden D, Germanos P, Gordon J, Tocchini L. The Cost-effectiveness of Dabigatran and the Opportunity Cost of Delayed Subsidised Access in Australia. Value Health. 2013 Nov;16(7):A526-A527.

Papadopoulos G, Tilden D, Aristides M. Review of trends in the appraisals of manufacturers' submissions to the Australian Pharaceutical Benefits Scheme since 2005. Value Health. 2013 May;16(3):A260-A261.

2012

Makino K, Charles H, Tilden D, Cottrell S, Mudge M, Christova L, Van Bavel J, West B, Woodgate AM. Health Economic Evaluation of Preservative-Free Tafluprost Versus Preserved Latanoprost in the Treatment of Open-Angle Glaucoma or Ocular Hypertension (OH). Value Health. 2012 Nov;15(7):A643.

2011

Tilden D, Germanos P, Gordon J, Tocchini L, Monz B. Cost-Effectiveness of Dabigatran for the Prevention of Stroke in Patients with Non-Valvular Atrial Fibrillation in Australia. Value Health. 2011 Nov;14(7):A375.

Christova L, Cottrell S, Mudge M, Tilden D, Harvey C. A Systematic Review of Observational Studies of Patients With Ocular Hypertension or Glaucoma Receiving Long Term Topical Eye Therapies. Value Health. 2011 Nov;14(7):A510.

Tilden D, Cottrell S, Tocchini L, Jayaram N, Sinani R, Barnes D. A Modelled Economic Evaluation of Firazy® (Icatibant) for Symptomatic Treatment of Acute Attacks of Hereditary Angioedema (HAE) in Adults with C1-Esterase-Inhibitor (C1-INH) Deficiency. Value Health. 2011 Nov;14(7):A322-A323.

Cottrell S, Tilden D, Jayaram N, Sinani R, Barnes D. Hereditary Angioedema Health State Utility Valuation Study from the persepective of a Representative Sample of the Australian General Public. Value Health. 2011 Nov;14(7):A324.

Tilden D, Cottrell S, Tocchini L, Frenzel C, Bonney MA. Identifying the patient population where treatment of severe Allergic Asthma with Omalizumab (Xolair®) exhibits optimal Cost-Effectiveness in Australia. Value Health. 2011 Nov;14(7):A492-A493.

Tilden D, Jackson D, Tay-Teo K, Van Bavel J. Assessing the cost effectiveness of broadening access to Alendronate for the prevention of Osteoporotic Frature in Australia. Value Health. 2011 Nov;14(7):A309-A310.

2010

Bloch M, Farris M, Tilden D, Gowers A, Cunningham N. 2010. Triple-class HIV antiretroviral therapy failure in an Australian primary care setting. Sex Health. 7(1):17–24.

Saridogan E, Tilden D, Sykes D, Davis N, Subramanian D. 2010. Cost-analysis comparison of outpatient see-and-treat hysteroscopy service with other hysteroscopy service models. J Minim Invasive Gynecol. 17(4):518–25.

Tilden D, Jackson D, LeReun C, Harvey C, Price B, Chaudhary M, van Bavel J. 2010. A modelled economic evaluation of raltegravir compared to standard practice in Australia for treatment-naïve patients with HIV. ISPOR 4th Asia Pacific Congress. 5–7 September 2010. Phuket, Thailand. BEST POSTER RESEARCH PRESENTATION AWARD WINNER

2009

Cottrell S, LeReun C, Robinson P, Tilden D. 2009. Preference and willingness-to-pay study to assess the value of an anticoagulation therapy modelled on dabigatran etexilate using discrete choice analysis: A UK pilot study of atrial fibrillation patients naïve to warfarin. ISPOR 12th Annual European Congress. 24–27 October 2009, Paris, France. Poster presentation.

Jackson D, Lee J, Adams J, Gordois A. 2009. Long term cost-effectiveness of docetaxel plus cyclophosphamide compared to doxorubicin plus cyclophosphamide as adjuvant treatment for women with operable breast cancer. ISPOR 12th Annual European Congress. 24–27 October 2009, Paris, France. Poster presentation.

Robinson P, Cottrell S, Tilden D, LeReun C. 2009. Preference and willingness-to-pay study to assess the value of an anticoagulation therapy modelled on dabigatran etexilate using discrete choice analysis: A UK pilot study of atrial fibrillation patients receiving warfarin. ISPOR 12th Annual European Congress. 24–27 October 2009, Paris, France. Poster presentation.

Tilden D, Lee J. 2009. Cost-effectiveness of extended versus nonextended prophylaxis with enoxaparin in high-risk surgical patients in Australia. ISPOR 12th Annual European Congress. 24–27 October 2009, Paris, France. Poster presentation.

Walker M, Lykopoulos K, McLeod E, Cottrell S, Christova L. 2009. Impact of brain metastases on health care costs in metastatic breast cancer: A multi-national study. J Clin Oncol, ASCO Annual Meeting Proceedings. 27(15S):6555.

2008

Bhatti T, Makino K, Guarnieri C, Gordois A, Cotter T, Perez D, Bishop J, Glass P. 2008. Cost-effectiveness analysis of smoking cessation pharmacotherapies in Australia. ISPOR 3rd Asia-Pacific Conference, Seoul, Korea, September 2008. Poster presentation.

Bishop J, Glass P, Tracey E, Hardy M, Warner K, Makino K, Gordois A, Wilson J, Guarnieri C, Feng J, Sartori L. 2008. Health economics review of bowel cancer screening in Australia. Cancer Institute NSW, August 2008.

Cottrell S, Tilden D, Robinson P, Bae J, Arellano J, Edgell E, Aristides M, Boye KS. 2008. A modeled economic evaluation comparing atomoxetine with stimulant therapy in the treatment of children with attention-deficit/hyperactivity disorder in the United Kingdom. Val Health. 11(3): 376–388.

Cottrell S, Walker M, Scheijbeler H, Christova L, Hertel N, Hass B, Behrens M, Roux E, Amonkar M, Aristides M. 2008. Impact of brain metastases on health care costs associated with the management of patients with metastatic breast cancer in France and Germany. Eur J Cancer. 6(7):176.

Feng J, Yuen C, Jackson D. 2008. Cost-effectiveness of enoxaparin as prophylactic therapy versus unfractionated heparin or no prophylaxis in hospitalised medical patients. ISPOR 11th Annual European Congress. 8–11 November 2008, Athens, Greece. Poster presentation.

Martin A, Cottrell S, Standaert B. 2008. Estimating utility scores in young children with acute rotavirus gastroenteritis in the UK. J Med Economics. 11(3): 471–484.

Mazzaglia G, Yurgin N, Boye KS, Trifirò G, Cottrell S, Allen E, Filippi A, Medea G, Cricelli C. 2008. Prevalence and antihyperglycemic prescribing trends for patients with type 2 diabetes in Italy: a 4 year retrospective study from national primary care data. Pharmacol Res. 57(5):358–63.

Medical Services Advisory Committee. 2008. Endoscopic ultrasound guided fine-needle aspiration for the staging of non-small cell lung cancer and the diagnosis of mediastinal masses. May 2007. Assessment report. Department of Health and Ageing, Commonwealth of Australia. Canberra.

Perez D, Cotter T, Makino K, Bhatti T, Gordois A, Guarnieri C, Lewis S, Glass P, Bishop J. 2008. Pharmacotherapy evaluation: drugs that assist smoking cessation. Sydney: Cancer Institute NSW. October 2008.

2007

Behrens M, Relf C, Cottrell S, Aristides M, Amonkar M, Walker M. 2007. Management of patients with metastatic breast cancer who progress on trastuzumab: a study of patients in Germany. [Die Behandlung von Patienten mit metastasiertem Brustkrebs nach Progress unter Trastuzumab. Eine deutsche Patientenstudie]. Presentation at the Gemeinsame Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Onkologie, October 2007, Basel, Switzerland.

Cottrell S, Allen E, Pascoe K, Sullivan T, LeReun C, Brown J, Lorenzo M, Aristides M. 2007. Preference and willingness-to-pay study to assess the value of atomoxetine using discrete choice analysis: UK parents perspective. Val Health. 10(3):A86.

Diamantopoulos A, Lorenzo M, Happich M, Cottrell S, Scheijbeler H. 2007. A cost-utility analysis of atomoxetine against current stimulant therapies for the treatment of children with attention deficit/hyperactivity disorder (ADHD) in Germany. Val Health. 10(6):A298.

Fitzgerald PB, Montgomery W, de Castella AR, Filia KM, Filia SL, Christova L, Jackson D, Kulkarni J. 2007. Australian Schizophrenia Care and Assessment Programme: real-world schizophrenia: economics. Aust NZ J Psychiatry. 41(10):819–29.

Starling N, Tilden D, White J, Cunningham D. 2007. Cost-effectiveness analysis of cetuximab/irinotecan vs. active/best supportive care for the treatment of metastatic colorectal cancer patients who have failed previous chemotherapy treatment. Br J Cancer. 96(2):206–212.

Tilden D, Mariz S, O’Bryan-Tear G, Bottomley J, Diamantopoulos A. 2007. A lifetime modelled economic evaluation comparing pioglitazone and rosiglitazone for the treatment of type 2 diabetes mellitus in the UK. Pharmacoeconomics. 25(1):39–54.

2006

Adams J, Nand V, LeReun C, Mudge M, Crowley S, Eggleston A, Schrover R, Brown A. 2006. Assessing the health and economic impact of schizophrenia on carers: a pilot study. ISPOR 2nd Asia-Pacific Conference. Shanghai, China 5–7 March 2006. Poster presentation.

Adams J, Nand V, LeReun C, Mudge M, Crowley S, Eggleston A, Schrover R, Brown A. 2006. The impact of schizophrenia on caregivers: burden of illness and quality of life. ISPOR 2nd Asia-Pacific Conference. Shanghai, China 5–7 March 2006. Poster presentation.

Goodyer L, Cottrell S, Martin A, Powell J, Fitzgerald P. 2006. Preference and willingness-to-pay study to assess the value of anti-malarial chemoprophylactic medications using discrete choice analysis: a study of travellers from the UK. Northern European Conference on Travel Medicine, Edinburgh, Scotland, June 2006. Poster presentation.

Martin A, Cottrell S. 2006. Estimating utility in rotavirus gastroenteritis in children under five in the UK. Val Health. 9(6): A258.

Montgomery B, Christova L, Mudge M, Davey P. 2006. Use patterns and outcomes associated with typical depot antipsychotic agents in the Schizophrenia Care Assessment Program (SCAP) in Australia. ISPOR 11th Annual International Meeting. 20–24 May 2006. Philadelphia, Pennsylvania, USA. Podium presentation.

Price N, Davey P, Mudge M, Fitzgerald B, Rajan N, Montgomery B. 2006. Cost-effectiveness of olanzapine versus lithium for the prevention of relapse in bipolar I disorder in Australia. ISPOR 11th Annual International Meeting. 20–24 May 2006. Philadelphia, Pennsylvania, USA. Poster presentation.

Tilden D, Cottrell S, Robinson P, Aristides M, Wait S, Hausdorff W, Bonfatti L. 2006. Developing a quasi-dynamic model for evaluating vaccines against Streptoccocus pneumoniae in infants. 5th International Symposium on Pneumococci and Pneumococcal Diseases. 2–6 April 2006, Alice Springs, NT, Australia. Poster presentation.

Tilden D, Pascoe K, Higashi MK, Marelli C, Kennedy L, Scheijbeler H, Aristides M. 2006. Towards a modelled economic evaluation to identify the optimal population for screening of coronary artery disease. ISPOR 9th Annual European Congress. 28–31 October 2006, Copenhagen, Denmark. Poster presentation.

Yurgin NR, Secnik K, Cottrell S, Fitzgerald P. 2006. Blood glucose monitoring recommendations and practices in patients with type 2 diabetes: a survey of healthcare professionals and patients in the UK. Val Health. 9(3): A37.

2005

Bae J, Arellano J, Aristides M, Cottrell S, Edgell E, Robinson P, Tilden D. 2005. A modelled economic evaluation comparing atomoxetine with stimulant therapy in the treatment of children with attention-deficit/hyperactivity disorder in the United Kingdom. Presentation at the 13th Congress of the Association of European Psychiatrists, Munich, Germany, April 2005. Poster presentation.

Brown B, Odeyemi IA, Christova L, Aristides M, Tilden D. 2005. Using the general practice research database to estimate the incidence, prevalence and management of hyperhidrosis in the United Kingdom. ISPOR 8th Annual European Congress. 6–8 November 2005, Florence, Italy. Poster presentation.

Cottrell S, Richardson R, Lewis S, Yanka E, Chambers M. 2005. Use of contrast echocardiography: A review of clinical data using a systematic approach. Val Health. 8(6):A97.>

Davey P, Price N, Lees M, Makino K, Birinyi-Strachan L, Frost M. 2005. Comparison of reimbursement systems of various countries in Central and Eastern Europe, Africa, Middle East and Asia. ISPOR Connections. 11(1):4–6.

Fitzgerald P, Tilden D, Aristides M. 2005. Analysis of quality of life data from different utility instruments: an example using imputation. ISPOR 8th Annual European Congress. 6–8 November 2005, Florence, Italy. Poster presentation.

Goodyer L, Cottrell S, Gandhi G, Aristides M. 2005. Preference and willingness-to-pay study to assess the value of anti-malarial chemoprophylactic medications using discrete choice analysis: A UK pilot study. 9th Conference of the International Society of Travel Medicine, May, 2005, Lisbon, Portugal. Poster presentation.

Laing A, Cottrell S, Robinson P, Veraart C, Tilden D, Aristides M. 2005. A modeled economic evaluation comparing atomoxetine with current therapies for the treatment of children with attention deficit/hyperactivity disorder (ADHD) in the Netherlands. ISPOR 8th Annual European Congress. 6–9 November 2005, Florence, Italy. Poster presentation.

Makino K, Matsushita T, Davey P, Narita M, Mori S, Kimuro Y. 2005. A psychiatric hospital revenue and profitability model for the treatment of patients with schizophrenia in Japan. ISPOR 10th Annual Meeting. 15–18 May 2005, Washington DC, USA. Poster presentation.

Medical Services Advisory Committee. 2005. High-energy transurethral microwave thermotherapy for benign prostatic hyperplasia. November 2005. Assessment report 1076. Department of Health and Ageing, Commonwealth of Australia. Canberra.

Mudge MAC, Davey PJ, Coleman KA, Montgomery W, Croker VS, Mullen K, Castle DJ. 2005. A comparison of olanzapine versus risperidone for the treatment of schizophrenia - a meta-analysis of randomised clinical trials. Int J Psychiatry Clin Prac. 9:3–15

Novello S, Kielhorn A, Stynes G, Selvaggi G, De Marinis F, Maestri A, Foggi P, Tilden D, Tonato M, Crinò L, Rinaldi M, Migliorino M, Scagliotti GV. 2005. Cost-minimisation analysis comparing gemcitabine/cisplatin, paclitaxel/carboplatin and vinorelbine/cisplatin in the treatment of advanced non-small cell lung cancer in Italy. Lung Cancer. 48(3):379–87.

Secnik K, Matza LS, Cottrell S, Edgell E, Tilden D, Mannix S. 2005. Health state utilities for childhood attention-deficit/hyperactivity disorder based on parent preferences in the United Kingdom. Med Decis Making. 25:56–70.

Richardson R, Cottrell S, Aristides M, Chambers M. 2005. Cost effectiveness of contrast echocardiography in the diagnosis of coronary artery disease. Val Health. 8(6):A98.

Stynes G, Gatzemeier U, Thatcher N, Bhalla S, Aristides M, Leschinger M, Tilden D. 2005. Do the published toxicity data from clinical trials in oncology give the full picture? An example using pemetrexed and docetaxel. Proceedings of the American Society of Clinical Oncology Annual Meeting, 13–17 May 2005, Orlando, Florida, USA. Poster presentation.

Tilden D, Hill G, Watt M, Bhalla S. 2005. A pilot study assessing the quality of life impact of adverse events experienced by advanced non-small-cell lung cancer patients receiving second-line chemotherapy. ISPOR 8th Annual European Congress. 6–8 November 2005, Florence, Italy. Poster presentation.

Tilden D, Richardson R, Nyhus K, Robinson P, Cottrell S. 2005. A modelled economic evaluation of atomoxetine (strattera) for the treatment of three patient groups with attention deficit hyperactivity disorder. ISPOR 8th Annual European Congress. 6–9 November 2005, Florence, Italy. Poster presentation.

Tilden D, Thurley D, White J, Aristides M. 2005. The cost-effectiveness of cetuximab in combination with irinotecan for the treatment of patients with egfr-expressing metastatic colorectal cancer after failure of irinotecan-including cytotoxic therapy in Scotland. ISPOR 8th Annual European Congress. 6–8 November 2005, Florence, Italy. Poster presentation.

Tilden D, Mariz S, Diamantopoulos A, O'Bryan-Tear G. 2005. A lifetime modelled economic evaluation comparing pioglitazone and rosiglitazone for the treatment of type 2 diabetes mellitus in the UK. ISPOR 8th Annual European Congress. 6–9 November 2005, Florence, Italy. Poster presentation.

2004

Bischoff H, Hamann M, Stynes G, Bhalla S, Tilden D, Kielhorn A. 2004. Comparative costs of gemcitabine/cisplatin, paclitaxel/carboplatin and vinorelbine/cisplatin in the treatment of non-small-cell lung cancer in Germany. ISPOR 7th Annual European Congress. 24–26 October 2004, Hamburg, Germany. Poster presentation.

Davey P, Price N, Lees M, Birinyi-Strachan L, Makino K, Mudge M. 2004. A retrospective comparison of the cost-effectiveness of olanzapine for the treatment of schizophrenia in selected non-OECD countries. ISPOR 9th Annual International Meeting. 16–19 May 2004, Arlington, VA, USA. Poster presentation.

Davey P, Lees M, Makino K, Price N, Birinyi-Strachan L. 2004. Comparison of reimbursement systems of various countries in Central and Eastern Europe, Africa and Middle East. ISPOR 9th Annual International Meeting. 16–19 May 2004, Arlington, VA, USA. Podium presentation.

Gordois A, Mudge M, Davey P, Aldridge G, Nobes M, Lees M, Toohey M. 2004. The cost-effectiveness of sirolimus with cyclosporine withdrawal versus low dose sirolimus and continued cyclosporine with initiated within four months of renal transplantations. ISPOR 9th Annual International Meeting. 16–19 May 2004, Arlington, VA, USA. Poster presentation.

Kielhorn A, Dilla T, Stynes G, Tilden D, Bhalla S. 2004. Costs of treating advanced non-small-cell lung cancer in Spain using gemcitabine in combination with cisplatin: a comparison with other second-generation novel agents. ISPOR 7th Annual European Congress. 24–26 October 2004, Hamburg, Germany. Poster presentation.

Kielhorn A, Stynes G, Bhalla S, Tilden D. 2004. A cost comparison of Gemzar plus cisplatin with other novel agents in the treatment of non-small-cell lung cancer in Italy. ISPOR 7th Annual European Congress. 24–26 October 2004, Hamburg, Germany. Poster presentation.

Launois R, Avoinet S, Le Lay K, Tilden D, Bhalla S, Kielhorn A, Chemali N. 2004. Gemzar retrospective economic analysis of clinical trials (GREAT2): a patient-level cost comparison of three chemotherapy regimens in the treatment of non-small-cell lung cancer in France. ISPOR 7th Annual European Congress. 24–26 October 2004, Hamburg, Germany. Poster presentation.

Medical Services Advisory Committee. 2004. Faecal occult blood testing for population health screening. May 2004. Assessment report. Department of Health and Ageing, Commonwealth of Australia, Canberra.

Price N, Davey P, Mudge M, Fitzgerald B, Rajan N, Montgomery W. 2004. Cost-effectiveness of olanzapine versus lithium for the prevention of relapse in bipolar I disorder in Australia. ISPOR 2nd Asia-Pacific Conference. 5–7 March 2006, Shanghai, China. Poster presentation.

Robinson P, von der Maase H, Bhalla S, Kielhorn A, Aristides M, Brown A, Tilden D. 2004. Cost-utility analysis of the GC versus MVAC regimens for the treatment of locally advanced or metastatic bladder cancer. Expert Rev Pharmacoeconomics Outcomes Res. 4(1):27–38.

Schiller J, Tilden D, Aristides M, Lees M, Kielhorn A, Maniadakis N, Bhalla S. 2004. Retrospective cost analysis of gemcitabine in combination with cisplatin in non-small cell lung cancer compared to other combination therapies in Europe. Lung Cancer. 43(1):101–112.

Secnik K, Cottrell S, Matza S, Edgell E, Aristides M, Tilden D, Burridge J, Mannix S. 2004. Assessment of health state utilities for attention-deficit/hyperactivity disorder in children using parent-based standard gamble scores. Val Health. 7 (3): 236.

Secnik K, Cottrell S, Matza L, Edgell E, Aristides M, Tilden D, Burridge J, Mannix S. 2004. Assessment of health state utilities for attention-deficit/hyperactivity disorder in children using parent-based standard gamble scores. ISPOR 9th Annual International Meeting. 16–19 May 2004, Arlington, VA, USA. BEST NEW INVESTIGATOR PODIUM RESEARCH PRESENTATION.

Secnik K, Cottrell S, Matza L, Edgell E, Aristides M, Tilden D, Burridge J, Mannix S. 2004. Assessment of health state utilities for attention-deficit/hyperactivity disorder in children using parent-based standard gamble scores. ISPOR Bulletin. June 2004.

Stynes G, Adams J, Tilden D, Garrett S, Wilson J. 2004. The burden of ankylosing spondylitis in Australia: an epidemiological and cost of illness model. ISPOR 7th Annual European Congress. 24–26 October 2004, Hamburg, Germany. Poster presentation.

Stynes G, Tilden D, Swift M, Cockle S, Haycox A, Aristides M. 2004. The cost-effectiveness of pioglitazone in combination with metformin in the treatment of type 2 diabetes mellitus in Scotland. ISPOR 7th Annual European Congress. 24–26 October 2004, Hamburg, Germany. Poster presentation.

Tilden D, Chapman J, Davey P, Solly M, Crowley S. 2004. A decision-analytic evaluation of valaciclovir prophylaxis for the prevention of cytomegalovirus infection and disease in renal transplantation. Clin Transplant. 18(3):312–320.

Tilden D, Mernagh P, Fitzgerald P, Adams J, Schulz M, van Bavel J, Davey P. 2004. Patient preference and willingness-to-pay for Vioxx as a treatment for osteoarthritis relative to NSAIDs. ISPOR 9th Annual International Meeting, 16–19 May 2004, Arlington VA USA. Poster presentation.

Tilden D, Stynes G, Adams J, Garrett S. 2004. Quantifying disease severity as a determinant of costs and quality of life in patients with ankylosing spondylitis in Australia. ISPOR 7th Annual European Congress. 24–26 October 2004, Hamburg, Germany. Poster presentation.

Tilden D, Stynes G, Swift M, Cockle S, Haycox A, Aristides M. 2004. The value of oral monotherapy alternatives in the first-line treatment of type 2 diabetes mellitus. ISPOR 7th Annual European Congress. 24–26 October 2004, Hamburg, Germany. Poster presentation.

Watkins J, Kielhorn A, Bhalla S, Tilden D, Stynes G. 2004. Does gemcitabine plus cisplatin provide value for money in the treatment of advanced non-small-cell lung cancer in the UK? ISPOR 7th Annual European Congress. 24–26 October 2004, Hamburg, Germany. Poster presentation.

2003

Adams J, Tilden D, Mernagh P. 2003. Utility valuation from the patient perspective of treatment outcomes in osteroarthritis. ISPOR 6th Annual European Congress. 9–11 November 2003, Barcelona, Spain. Poster presentation.

Aristides M, Jackson D, Liepa AM, Leighl N, Shepherd FA. 2003. Costs of managing toxicities in non-small cell lung cancer with pemetrexed compared to docetaxel as second-line chemotherapy: application to the UK setting. ISPOR 6th Annual European Congress, 9–11 November 2003, Barcelona, Spain. Poster presentation.

Bischoff H, Tilden D, Kielhorn A, Heuser C. 2003. Gesamttherapiekosten—Analyse fur platin-haltige neue chemotherapien (Analysis of costs for chemotherapy with platinum-based regimes: Gemcitabine retrospective economic analysis of clinical trials (GREAT). Krakenhauspharmazie 24(10):439–445.

Cockle SM, Jackson D, Aristides M, Sykes DP. 2003. The burden of osteoporosis in Europe: an epidemiological model. ISPOR 6th Annual European Congress. 9–11 November 2003, Barcelona. Poster presentation.

Croker V, Coleman K, Mudge M, Aldridge G, Davey P, Castle D. 2003. A meta-analysis of randomised clinical trials comparing olanzapine with other antipsychotic agents used in the treatment of schizophrenia. International Congress of Schizophrenia Research, 29 March–2 April 2003, Colorado Springs, CO, USA. Poster presentation.

Davey P, Lees M, Makino K. 2003. Mandatory inclusion of pharmacoeconomics in drug funding: lessons from the Australian approach 1993–2003. ISPOR 1st Asia Pacific Conference. 1–3 September 2003, Kobe, Japan. Poster presentation.

Davey P, Mudge M, Croker V, Aldridge G, Fitzgerald P. 2003. A meta-analysis and common comparator analysis of olanzapine versus ziprasidone and aripiprazole. ISPOR 8th Annual International Meeting. 18–21 May 2003, Arlington, VA. Poster presentation.

Gillberg C, Lothgren M, Fitzgerald P, Cottrell S, Burridge J, Aristides M. 2003. Atomoxetine versus methylphenidate as a treatment for ADHD in children and adolescents: A meta-analysis of safety data incorporating active comparator and placebo controlled trials. European Society for Child and Adolescent Psychiatry (ESCAP) 12th International Congress. September 2003, Paris, France. Poster presentation.

Jackson D, Cockle SM, Aristides M, Sykes DP. 2003. The cost of osteoporotic fractures in females in the UK: an epidemiological model. ISPOR 6th Annual European Congress, 9–11 November 2003, Barcelona, Spain. Poster presentation.

Lees M, Davey P, Price N, Aldridge G, Mudge M, Stokes J. 2003. Economic evaluation of photodynamic therapy with verteporfin for small subfoveal CNV lesions: the case for Australia. ISPOR 8th Annual International Meeting. 18–21 May 2003, Arlington, VA. Poster presentation.

Medical Services Advisory Committee. 2003. LeukoScan—For use in diagnostic imaging of the long bones and feet in patients with suspected osteomyelitis, including those with diabetic foot ulcers. May 2003. Assessment report. Department of Health and Ageing, Commonwealth of Australia, Canberra.

Medical Services Advisory Committee. 2003. M2Aâ Capsule Endoscopy. August 2003. Assessment report. Department of Health and Ageing, Commonwealth of Australia, Canberra.

Montgomery W, Croker V, Coleman K, Davey P, Jackson D, Mullen K. 2003. Valuing the safety and efficacy of treatments for schizophrenia by means of a quadrant approach and time trade off survey. International Congress on Schizophrenia Research. 29 March–2 April 2003, Colorado Springs, CO, USA.

Tilden D, Aristides M, Stynes G, Lis J, Orlewska E, Krzakowski M, Jassem J, Wlodarczyk H, Zaluski J. 2003. The cost of gemcitabine/cisplatin compared with four other novel chemotherapeutic agents in Poland. ISPOR 6th Annual European Congress. 9–11 November 2003, Barcelona, Spain. Poster presentation.

Tilden D, Schulz M, Davey P, Noble I. 2003. A utility valuation study assessing treatment outcomes in osteoarthritis. ISPOR 8th Annual International Meeting. 18–21 May 2003, Arlington, VA. Poster presentation.

2002

Adams J, Davey P, Jackson D, Croker V, Aristides M, Mullen K, Montgomery W. 2002. Using a community sample to derive utility values of schizophrenia treatment outcomes from a time tradeoff methodology. ISPOR 7th Annual International Meeting. 19–22 May 2002, Arlington, VA. Poster presentation.

Aristides M, Lees M, Tilden D, Kielhorn A, Stynes G. 2002. Gemzar retrospective economic analysis of clinical trials (GREAT) in the treatment of non-small-cell lung cancer: a multi-country cost-minimisation analysis. ISPOR 5th Annual European Congress, 3–5 November 2002, Rotterdam, The Netherlands. Poster presentation.

Aristides M, Tilden D, Lees M, Kielhorn A, Bhalla S. 2002. In the UK Gemzar doublet has lowest total treatment costs for NSCLC compared to four other chemotherapy doublets. ISPOR 5th Annual European Congress. 3–5 November 2002, Rotterdam, The Netherlands. Poster presentation.

Aristides M, Tilden D, Robinson P, Weston A, Davey P, Aldridge G. 2002. A decision-analytic model to compare the cost of methyl aminolevulinate photodynamic therapy with standard treatments in the UK for difficult-to-treat basal cell carcinoma and actinic keratosis. ISPOR 7th Annual International Meeting. 19–22 May 2002, Arlington, VA. Poster presentation.

Christova L, Davey P, Jackson D, Montgomery W, deCastella A, Fitzgerald P, Brewer K, Filia K, Collins J, Kulkarni J. 2002. The healthcare costs of schizophrenia in Australia: 18-month follow-up results. ISPOR 5th Annual European Congress. 3–5 November 2002, Rotterdam, The Netherlands. Poster presentation.

Kielhorn A, Aristides M, Tilden D, Bhalla S. 2002. Average total cost of treating advanced non-small-cell lung cancer patients in Spain using various chemotherapy doublets. ISPOR 5th Annual European Congress. 3–5 November 2002, Rotterdam, The Netherlands. Poster presentation.

Kielhorn A, Maniadakis N, Aristides M, Lees M, Tilden D. 2002. Retrospective cost analysis of Gemzar™ in combination with cisplatin in non-small cell lung cancer compared to other combination therapies in Germany. ISPOR 7th Annual International Meeting, 19–22 May 2002, Arlington, VA. Poster presentation.

Medical Services Advisory Committee. 2002. Evaluation of near patient cholesterol testing using the Cholestech LDX. August 2001. Assessment report. Department of Health and Ageing, Commonwealth of Australia, Canberra.

Medical Services Advisory Committee. 2002. Low intensity ultrasound treatment for acceleration of bone fracture healing—Exogen™ bone growth stimulator. November 2001. Assessment report. Department of Health and Ageing, Commonwealth of Australia, Canberra.

Schulz M, Noble I, Tilden D, Davey P, Crowley S. 2002. Modelled cost-utility analysis of rofecoxib and traditional non-steroidal therapies for treatment of chronic osteoarthritis. ISPOR 7th Annual International Meeting. 19–22 May 2002, Arlington, VA. Poster presentation.

Tilden D, Aristides M, Kielhorn A, Bhalla S. 2002. Major determinants of cost in advanced non-small-cell lung cancer chemotherapy regimens in France. ISPOR 5th Annual European Congress. 3–5 November 2002, Rotterdam, The Netherlands. Poster presentation.

Tilden D, Aristides M, Meddis D, Burns T. 2002. An economic evaluation of quetiapine and haloperidol in the treatment of schizophrenic patients partially responsive to previous antipsychotics. Clin Therapeutics. 24(10):1648–1667.

Tilden D, Aristides M, Stynes G, Kielhorn A, Bhalla S. 2002. A comparison of the costs of gemcitabine/cisplatin and gemcitabine/carboplatin combination regimens in the treatment of advanced NSCLC in the UK and France. ISPOR 5th Annual European Congress. 3–5 November 2002, Rotterdam, The Netherlands. Poster presentation.

2001

Ekert H, Brewin T, Boey W, Davey P, Tilden D. 2001. Cost-utility analysis of recombinant factor VIIa (NovoSeven) in six children with long-standing inhibitors to factor VII or IX. Haemophilia. 7(3):279–285.

Tilden D, Aristides M, Meddis D, Burns T. 2001. The cost-effectiveness of quetiapine in the treatment of schizophrenic patients partially responsive to previous antipsychotics: an economic analysis of the PRIZE study. ISPOR 4th Annual European Congress. 11–13 November 2001, Cannes, France. Poster presentation.

© Copyright THEMA Consulting. All Rights Reserved. Website Designers: Sonic Interactive